Clearmind Secures Approval for Psychedelic AUD Clinical Trial

Clearmind Medicine Inc., a biotech firm centered on developing psychedelic-based treatments for significant health issues, has been granted permission by the Israeli Ministry of Health to initiate a phase I/IIa clinical trial. The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, an oral capsule derived from MEAI, for patients with alcohol use disorder (AUD). The study, set to be conducted in Israel and with additional sites in the U.S., will be headed by Prof. Mark Weiser at the Sheba Medical Center, Tel Aviv, and aims to determine the optimal dosage and effects of CMND-100 on AUD subjects and healthy volunteers.
Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed enthusiasm about the milestone, highlighting the company's dedication to addressing the global alcoholism crisis with a novel, non-hallucinogenic treatment. The primary goal of the trial is to establish the tolerable dosage and understand the drug's safety profile, while secondary objectives include assessing the drug's preliminary efficacy in reducing alcohol cravings and consumption patterns.
The active component, MEAI, is a non-hallucinogenic psychoactive molecule that has shown promise in reducing alcohol consumption desires. It is believed to act on serotonergic and adrenergic receptors, which are crucial in alcohol intake regulation. Clearmind Medicine, listed on Nasdaq and other exchanges, is focused on commercializing psychedelic compounds as regulated treatments for health issues like AUD. The company holds an intellectual property portfolio and is proactive in seeking patents for its compounds.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!